Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.

Abstract in brief

• This text discusses a study that uses a mathematical model based on a personalized clinical cellcycle risk (CCR) score to predict how much benefit patients with newly diagnosed prostate cancer might get from adding androgen deprivation therapy (ADT) to radiation therapy (RT).
• The model shows that patients with higher CCR scores are more likely to benefit significantly from ADT, with an absolute risk reduction of up to 17.1% and a number needed to treat as low as 6, meaning fewer patients need treatment for one to benefit.
• Overall, the CCR score helps tailor treatment decisions by accurately estimating 10-year metastasis risk, allowing physicians and patients to make more personalized and informed choices about intensifying therapy.